Back to News
Market Impact: 0.35
Nuvation Bio Wins FDA Nod For Updated IBTROZI Label Showing 50-Month DOR In ROS1+ Lung Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
The FDA approved Nuvation Bio's supplemental New Drug Application for IBTROZI, updating its label with new long-term efficacy data for treatment-naïve patients with advanced ROS1-positive non-small cell lung cancer. The approval strengthens the drug's clinical positioning in its targeted NSCLC indication and is a positive regulatory milestone for Nuvation Bio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
NUVB0.82
More News
- UN mission finds evidence of U.S. war crimes in Iran; Washington rejects report
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- Warsh spooks investors, OpenAI's 'concerning' incidents, Boeing's production problems and more in Morning Squawk
- Waymo to launch robotaxis in Singapore, its first Southeast Asia market, by 2028
- UK Lawmakers Say Thames Creditors Have Been Joyriding Family Car
- Securitize jumps after regulators greenlight some tokenized U.S. stock trading